Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 16/20 | 0.79 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.78 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812659 | 0.89 | ADAMTS5 (1.00) | ADAMTS5ADAMTS4 | |
| SCHEMBL1814568 | 0.89 | ADAMTS5 (1.00) | ADAMTS5ADAMTS4 | |
| SCHEMBL3976904 | 0.89 | ADAMTS5 (1.00) | ADAMTS5ADAMTS4 | |
| SCHEMBL1815616 | 0.89 | ADAMTS5 (1.00) | ADAMTS5ADAMTS4 | |
| SCHEMBL1813188 | 0.88 | ADAMTS5 (1.00) | ADAMTS5ADAMTS4 | |
| SCHEMBL1813659 | 0.88 | ADAMTS5 (1.00) | ADAMTS5ADAMTS4 | |
| SCHEMBL1813190 | 0.88 | ADAMTS5 (1.00) | ADAMTS5ADAMTS4 | |
| SCHEMBL1812138 | 0.87 | ADAMTS5 (0.87) | ADAMTS5ADAMTS4 | |
| SCHEMBL1816094 | 0.87 | ADAMTS5 (0.84) | ADAMTS5ADAMTS4 | |
| SCHEMBL1812648 | 0.86 | ADAMTS5 (0.76) | ADAMTS5ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137079-A1 | INHIBITORS OF JMJD2C AS ANTICANCER AGENTS | The J. David Gladstone Institutes (US) | 2017-03-08 | — | — | EP | claimed |
| US-20170044107-A1 | Inhibitors of JMJD2C as Anticancer Agents | THE J. DAVID GLADSTONE INSTITUTES | 2017-02-16 | — | — | US | claimed |
| WO-2015167874-A1 | INHIBITORS OF JMJD2C AS ANTICANCER AGENTS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-11-05 | — | — | WO | claimed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | claimed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | claimed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044107-A1 | Inhibitors of JMJD2C as Anticancer Agents | KDM2A, KDM1B, KDM5C | ADAMTS5 4368/4885ADAMTS4 4534/4885ALOX12 3591/4885 |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | ADAMTS5 11/4885ADAMTS4 14/4885ALOX12 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.